Pre-made Cadonilimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Cadonilimab benchmark antibody (Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cadonilimab (AK104) is a novel, potential next-generation,first-in-classbi-specificPD-1/CTLA-4immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-088-1mg	1mg	Inquiry
GMP-Bios-ab-088-10mg	10mg	Inquiry
GMP-Bios-ab-088-100mg	100mg	Inquiry
GMP-Bios-ab-088-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-made Cadonilimab benchmark antibody (Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody)
INN Name	Cadonilimab
Target	PD-1;CTLA-4
Format	Bispecific Mixed mAb and scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1;na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2020
Year Recommended	na
Companies	Akeso Biopharma
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma
Conditions Discontinued	na
Development Tech	na